基于真实世界处方信息的蒲地蓝消炎口服液临床应用调查研究

Investigation of clinical application of Pudilan anti-inflammatory oral liquid based on real world prescription information

目的:了解蒲地蓝消炎口服液的临床使用现状,为蒲地蓝消炎口服液临床合理应用提供参考。方法:采用回顾性调查方式,抽取6家不同地区三甲中医院2017年含蒲地蓝消炎口服液的门诊、急诊处方12 465张,对使用科室、患者性别、患者年龄、单次用量、使用频次、日剂量、联合用药情况和处方诊断等进行统计分析。结果:蒲地蓝消炎口服液的使用在儿科比例最大,高达79.46%;年龄与单次剂量(r=0.190)和日剂量(r=0.172)相关性较弱;临床单用的情况较多,达到63.22%;临床主要用于呼吸道感染(53.88%)、咳嗽(14.08%),在紫癜性疾病(3.91%)等方面亦有较多使用。结论:蒲地蓝消炎口服液在儿科使用剂量与成人基本相同,可能存在安全隐患,同时其临床超说明书适应证使用十分普遍。

Objective To understand the current situation of clinical application of Pudilan anti-inflammatory oral liquid,and to provide reference for rational clinical use of Pudilan anti-inflammatory oral liquid.Methods By means of retrospective investigation,12 465 prescriptions of Pudilan anti-inflammatory oral liquid in outpatient and emergency department from 6 hospitals in different areas in 2017 were selected.The use of departments,patients′ gender,patients′ age,single dose,frequency of use,daily dose,combined use of drugs,and prescription diagnosis were analyzed statistically. Results Pudilan anti-inflammatory oral liquid accounted for the largest proportion in pediatrics,as high as 79.46%.However,there was a week correlation between the clinical dosage and age(single dose r=0.190,daily dose r=0.172). Single use was common in clinic,accounting for 63.22%.Pudilan anti-inflammatory oral liquid was not only primarily used in respiratory tract infectious diseases(53.88%)and cough(14.08%),but also used in purpura(3.91%)and other aspects.Conclusion The dosage of Pudilan anti-inflammatory oral liquid in pediatrics is basically the same as that in adults,and there may be potential safety hazards.At the same time,it is widely used in clinic beyond the indication of instructions.